KEGG   DISEASE: H00821Help
H00821                      Disease                                

Macular degeneration, including:
Age-related macular degeneration (ARMD);
Patterned dystrophy of retinal pigment epithelium (PDREP);
Retinal macular dystrophy 2 (MCDR2);
X-linked atrophic macular degeneration (MDXLA)
Macular degeneration is the physical breakdown of the central portion of the retina called the macula. Age-related macular degeneration (AMD/ARMD) is the leading cause of blindness. AMD is a complex disease caused by the combination of genetic predisposition and environmental factors. Using genome linkage scan and association studies, multiple potentially causative genes have been identified. In AMD, there are two phenotypes, atrophic/ dry and neovascular/ wet. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is usually characterized by the abnormal growth of new blood vessels under the macula, which causes severe loss of vision. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD.
Nervous system disease; Eye disease
Human diseases [BR:br08402]
 Nervous system diseases
  Other nervous and sensory system diseases
   H00821  Macular degeneration
Human diseases in ICD-10 classification [BR:br08403]
 7. Diseases of the eye and adnexa (H00-H59)
  H30-H36  Disorders of choroid and retina
   H35  Other retinal disorders
    H00821  Macular degeneration
BRITE hierarchy
ABC transporters
Nucleotide excision repair
Toll-like receptor signaling pathway
Cytokine-cytokine receptor interaction
Chemokine signaling pathway
(ARMD1) HMCN1 [HSA:83872] [KO:K17341]
(ARMD2) ABCA4 [HSA:24] [KO:K05644]
(ARMD3) FBLN5 [HSA:10516] [KO:K17340]
(ARMD4) HF1 [HSA:3075] [KO:K04004]
(ARMD5) ERCC6 [HSA:2074] [KO:K10841]
(ARMD6) RAX2 [HSA:84839] [KO:K09333]
(ARMD7) HTRA1 [HSA:5654] [KO:K08784]
(ARMD8) ARMS2 [HSA:387715]
(ARMD9) C3 [HSA:718] [KO:K03990]
(ARMD10) TLR4 [HSA:7099] [KO:K10160]
(ARMD11) CST3 [HSA:1471] [KO:K13899]
(ARMD12) CX3CR1 [HSA:1524] [KO:K04192]
(PDREP) PRPH2 [HSA:5961] [KO:K17343]
(MCDR2) PROM1 [HSA:8842] [KO:K06532]
Verteporfin [DR:D01162]
Bevacizumab [DR:D06409]
Ranibizumab [DR:D05697]
Laser photocoagulation
Haplotypes of the complement factor B (CFB) and complement component-2 (C2) genes, which encode regulatory proteins in the same alternate complement pathway as CFH, have been found in association with reduced risk of ARMD. A haplotype carrying deletion of the complement factor H-related genes CFHR1 and CFHR3 is also associated with reduced risk of ARMD.
CFB [HSA:629] [KO:K01335]
C2 [HSA:717] [KO:K01332]
CFHR1 [HSA:3078]
CFHR3 [HSA:10878]
Other DBs
Montezuma SR, Sobrin L, Seddon JM
Review of genetics in age related macular degeneration.
Semin Ophthalmol 22:229-40 (2007)
Baas DC, Despriet DD, Gorgels TG, Bergeron-Sawitzke J, Uitterlinden AG, Hofman A, van Duijn CM, Merriam JE, Smith RT, Barile GR, ten Brink JB, Vingerling JR, Klaver CC, Allikmets R, Dean M, Bergen AA
The ERCC6 gene and age-related macular degeneration.
PLoS One 5:e13786 (2010)
Ayyagari R, Demirci FY, Liu J, Bingham EL, Stringham H, Kakuk LE, Boehnke M, Gorin MB, Richards JE, Sieving PA
X-linked recessive atrophic macular degeneration from RPGR mutation.
Genomics 80:166-71 (2002)
Giuffre G, Lodato G
Vitelliform dystrophy and pattern dystrophy of the retinal pigment epithelium: concomitant presence in a family.
Br J Ophthalmol 70:526-32 (1986)
Michaelides M, Gaillard MC, Escher P, Tiab L, Bedell M, Borruat FX, Barthelmes D, Carmona R, Zhang K, White E, McClements M, Robson AG, Holder GE, Bradshaw K, Hunt DM, Webster AR, Moore AT, Schorderet DF, Munier FL
The PROM1 mutation p.R373C causes an autosomal dominant bull's eye maculopathy associated with rod, rod-cone, and macular dystrophy.
Invest Ophthalmol Vis Sci 51:4771-80 (2010)
PMID:21546780 (Drag)
Koss MJ, Lewicka-Chomont A, Schramm K, Rejdak R, Ohrloff C, Koch FH
Quadruple therapy leads to a sustained improvement of vision in patients with wet age-related macular degeneration.
Ophthalmologica 226:45-50 (2011)
PMID:21623685 (drag)
Mitchell P
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used  for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Curr Med Res Opin 27:1465-75 (2011)
Virgili G, Bini A
Laser photocoagulation for neovascular age-related macular degeneration.
Cochrane Database Syst Rev CD004763 (2007)

» Japanese version

DBGET integrated database retrieval system